The consolidated net profits attributable to the parent company of Minapharm Pharmaceuticals hit EGP 54.851 million in the first nine months of 2025, an annual plunge of 22.76% from EGP 71.018 million.

Minapharm Pharmaceuticals has signed a strategic cooperation agreement with Germany’s Bayer to localize drug production and boost pharma investments in Egypt.

Minapharm Pharmaceuticals (Minapharm) has incurred standalone net losses after tax amounting to EGP 12.107 million during the first half (H1) of 2024, versus net profits of EGP 77.484 million in the same period last year.

Minapharm Pharmaceuticals (Minapharm) (MIPH) reported a 91.9% year-on-year (YoY) decline in consolidated net profits attributable to the parent company for the first quarter (Q1) of 2024.

A block-trading transaction has been executed on 6.365 million shares of Minapharm Pharmaceuticals for EGP 1.275 million.

Minapharm Pharmaceuticals will pay the EGP 1.65 per share dividends to shareholders for 2023 on May 12th, according to a statement filed to the Egyptian Exchange (EGX) on April 24th.

Minapharm Pharmaceuticals (Minapharm) posted a consolidated loss after tax and minority interest of EGP 31.98 million in 2023, versus a profit of EGP 612.66 million in 2022.

Minapharm Pharmaceuticals (Minapharm) posted a 24.9% year-on-year (YoY) drop in standalone net profits after tax in 2023 to EGP 206.505 million, compared to EGP 274.913 million.

Minapharm Pharmaceuticals has cooperated with the France-based healthcare firm Sanofi to manufacture the anticoagulant drug Clexane at Minaoharm's factory.

Minapharm Pharmaceuticals (Minapharm) announced that its consolidated profit after minority interest plunged 68.12% year on year (YoY) during the first nine months of 2023, hitting EGP 143.100 million from EGP 448.810 million.

Minapharm Pharmaceuticals (Minapharm) posted a 70.6% year-on-year (YoY) drop in standalone profit after tax during the first nine months of 2023 to EGP 62.869 million, compared to EGP 214.094 million.

Minapharm Pharmaceuticals is an Egypt-based company engaged in the production and distribution of pharmaceutical products. It distributes its products within and outside Egypt.

Minapharm Pharmaceuticals is an Egypt-based company engaged in the production and distribution of pharmaceutical products. It is in cooperation with several international pharmaceutical companies and it distributes its products within and outside Egypt.

Minapharm Pharmaceuticals will pay the EGP 2.8 per share dividends to shareholders for 2022 on July 10th.

Minapharm Pharmaceuticals is an Egypt-based company engaged in the production and distribution of pharmaceutical products. It is in cooperation with several international pharmaceutical companies and it distributes its products within and outside Egypt.

Minapharm Pharmaceuticals is an Egypt-based company engaged in the production and distribution of pharmaceutical products. It is in cooperation with several international pharmaceutical companies and it distributes its products within and outside Egypt.

Minapharm Pharmaceuticals’ (MIPH) ordinary general meeting (OGM) has accredited disbursing cash dividends of EGP 2.8 per share to shareholders for 2022.

Minapharm Pharmaceuticals is an Egypt-based company engaged in the production and distribution of pharmaceutical products. It is in cooperation with several international pharmaceutical companies and it distributes its products within and outside Egypt.